0.4365  0.026 (6.28%)		10-24 16:00
Open: 0.41 High: 0.4472 Volume: 1,247,518		Pre. Close: 0.4107 Low: 0.41 Market Cap: 18(M)

Short term
Mid term
Targets	6-month :	0.62	1-year :	0.72
Resists	First :	0.53	Second :	0.62
Pivot price	0.44
Supports	First :	0.39	Second :	0.32
MAs	MA(5) :	0.41	MA(20) :	0.47
	MA(100) :	0.6	MA(250) :	1.23
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	16	D(3) :	13.4
RSI	RSI(14): 42
52-week	High :	3.89	Low :	0.39

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FBLG ] has closed above bottom band by 44.4%. Bollinger Bands are 4.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.45 - 0.45	0.45 - 0.45
Low:	0.41 - 0.41	0.41 - 0.41
Close:	0.43 - 0.44	0.44 - 0.44

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Sat, 11 Oct 2025
FibroBiologics, Inc. - Common Stock (NQ: - FinancialContent

Wed, 09 Jul 2025
Breakthrough: FibroBiologics Achieves Major Cost-Saving Milestone in Degenerative Disc Disease Treatment Development - Stock Titan

Mon, 16 Jun 2025
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing - GlobeNewswire

Tue, 10 Jun 2025
FibroBiologics names new CFO after going public last year - The Business Journals

Thu, 03 Apr 2025
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25… - Zacks Small Cap Research

Sat, 08 Feb 2025
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	42 (M)
Shares Float	32 (M)
Held by Insiders	19.5 (%)
Held by Institutions	12.3 (%)
Shares Short	966 (K)
Shares Short P.Month	918 (K)

EPS	-0.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.01
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-88.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.38
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	-1.22
PEG Ratio	0
Price to Book value	21.82
Price to Sales	0
Price to Cash Flow	-1.23

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.